Melanoma can come back, but whether it will depends heavily on the stage and characteristics of your original tumor. For thin melanomas under 0.8 mm, about 96% of patients remain recurrence-free at ten years. For thicker tumors, the odds shift: melanomas between 0.8 and 1.0 mm recur in roughly 1 in 10 patients, and those between 1.0 and 2.0 mm recur in about 1 in 6. The risk climbs further with more advanced stages. Understanding the specific factors that drive recurrence, when it’s most likely to happen, and what to watch for can help you stay ahead of it.
What Drives Recurrence Risk
The single biggest predictor of recurrence is how deep the original melanoma grew into your skin, measured in millimeters. A melanoma thicker than 4.0 mm carries roughly 6.7 times the recurrence risk of a thin one. Even a medium-depth tumor (2.0 to 4.0 mm) quadruples the risk compared to thinner lesions.
Beyond depth, several other features from your pathology report matter. Ulceration, meaning the skin over the tumor broke down, significantly increases recurrence risk. So does lymphovascular invasion, where melanoma cells are found inside tiny blood or lymph vessels near the tumor. A positive sentinel lymph node biopsy, indicating cancer had already reached the nearest lymph nodes, is another strong predictor. Being 65 or older at diagnosis also raises the likelihood.
These factors don’t work in isolation. A thin melanoma with no ulceration in a younger patient has a very different outlook than a thick, ulcerated melanoma that has already reached the lymph nodes. Your oncologist uses all of these features together to estimate your individual risk.
When Recurrence Is Most Likely
If melanoma is going to return, about 46% of recurrences show up within the first three years after diagnosis. That’s why follow-up visits are most frequent early on. But melanoma is unusual among cancers in that it can reappear much later. The median time between an early-stage diagnosis and metastatic disease is four years, and more than half of patients who eventually develop metastatic recurrence do so after that four-year mark.
The tail is long. Roughly 12% of recurrences happen between 7 and 10 years after the original diagnosis, another 8% between 10 and 12 years, and 12% surface beyond the 12-year mark. This pattern is why dermatologists recommend lifelong skin surveillance for melanoma survivors, not just a five-year window.
Where Melanoma Can Return
Recurrence takes three forms, each with different implications.
- Local recurrence means melanoma regrows within about 2 cm of the original surgical scar. This happens in roughly 4% of cases and is often the most treatable form of recurrence.
- Regional recurrence involves the nearby lymph nodes or the skin and tissue between the original site and those nodes (called in-transit metastases). Up to 10% of melanoma patients develop some form of locoregional recurrence. Regional nodal recurrence occurs in about 13% of cases overall.
- Distant recurrence means melanoma has spread to other organs. This is the most serious form and occurs in about 21% of cases across all stages. The most common sites are the lungs, brain, liver, bones, and intestines. Distant metastases to the gut can cause obstruction or bleeding, while metastases to the brain or liver may be silent for a time before causing symptoms.
How Adjuvant Therapy Changes the Odds
For patients with higher-risk melanoma (generally stage IIB and above), immunotherapy given after surgery can reduce the chance of recurrence by 40% to 50%. These treatments work by training your immune system to recognize and attack any remaining melanoma cells. Despite that significant reduction, nearly half of higher-risk patients still experience recurrence at some point, including some who recur while still receiving the therapy. The benefit is real but not absolute, which is why ongoing surveillance remains essential even after completing adjuvant treatment.
What to Watch For
Self-examination is one of the most practical things you can do. Check your skin regularly, including your surgical scar and the surrounding area. Enlist a family member to help examine hard-to-see areas like your back and scalp. You’re looking for new or changing moles anywhere on your body, not just near the original site. The ABCDE guidelines are a useful framework: asymmetry, irregular borders, uneven color, diameter larger than a pencil eraser, and any mole that is evolving or changing over time.
For local or in-transit recurrence, look for new bumps, nodules, or discolored spots on or near the scar. For regional recurrence, pay attention to any lumps or swelling in the lymph node areas closest to your original melanoma, such as the groin, armpit, or neck. Distant recurrence can produce symptoms depending on the organ involved: persistent headaches or neurological changes (brain), unexplained cough or shortness of breath (lungs), abdominal pain or changes in digestion (liver or intestines), or bone pain.
Follow-Up Schedules by Stage
How often you see your doctor depends on your original stage. For stage 0, I, and IIA melanoma, current guidelines recommend a full physical exam and complete skin check every 6 to 12 months for the first one to two years, then annually. For stage IIB and higher, visits are more frequent: every 3 to 6 months for the first two years, then every 6 to 12 months through year five, and annually after that.
Imaging is reserved for higher-risk patients. If your melanoma was stage IIB or above, brain scans are typically recommended every 3 to 12 months for the first two years and every 6 to 12 months from years three through five. Patients with a history of brain metastases or stage IIIC and above may need more frequent brain MRIs. Body imaging on a similar schedule helps detect distant recurrence before symptoms develop.
Living With the Uncertainty
The anxiety of wondering whether melanoma will return is one of the hardest parts of survivorship. The numbers offer some grounding. For early-stage, thin melanomas, the vast majority of patients never see their cancer again. Ten-year recurrence-free survival is 91.5% for melanomas thinner than 0.8 mm and 82% for those between 0.8 and 1.0 mm. Even for melanomas up to 2.0 mm thick, about three in four patients remain recurrence-free at a decade.
What you can control matters: keeping every follow-up appointment, doing regular self-skin exams, protecting your skin from UV damage to reduce the risk of a new primary melanoma, and knowing the specific warning signs for your situation. Recurrence is always possible with melanoma, sometimes even decades later, but for most patients it never happens.